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ABSTRACT
Dissolution studies have become of great significance because, in most cases, drug dissolution is the rate-limiting step in 
the absorption process. As occurs with solid oral dosage forms, heterogeneous dispersed systems (suspensions) could also 
have some problems with their in vitro dissolution.
The objective of this study was to evaluate the influence of excipients on the release of spironolactone from four 
alcohol-free suspensions (pharmaceutical compounding) of spironolactone 5 mg/mL suitable for pediatric use. 
In addition, the comparison of the physical and chemical stability of the suspensions stored at 4, 25, and 40 °C over 
a 60-day period has been studied. Rheological behavior, particle size, a prediction of long-term physical stability, pH, 
and assay of spironolactone by HPLC were assessed at preset times. The dissolution profile of each suspension was 
determined and compared with that of the commercial tablets. A microbiological study of the best formula was also 
performed. Chemically, the four spironolactone suspensions were stable for 60 days stored at three temperatures; Sus-
pension IV had optimum pH values and the highest recovery percentage. In terms of physical stability, sedimentation 
occurred in Suspension IV, and flotation of spironolactone occurred in Suspensions I, II, and III. Suspension III had the 
highest viscosity and the slowest drug release. Suspension IV was also microbiologically stable for 60 days. In conclusion, 
Suspension IV had the best properties. The least suitable form was Suspension III, as its high viscosity made it difficult to 
achieve homogeneous redispersion and it had the slowest dissolution profile.
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INTRODUCTION
Spironolactone is a competitive aldosterone antago-nist that acts at the distal convoluted renal tubule to increase sodium and water excretion and reduce 
potassium elimination (1). The use of spironolactone in 
infants and children was first reported in 1964 (2) when 
administration of the drug to three infants produced mod-
erate dieresis. Since then, spironolactone has been widely 
utilized in the management of congestive heart failure 
associated with congenital heart disease (3–5), broncho-
pulmonary dysplasia or chronic lung disease (5–7), and 
pediatric ascites (8, 9). 
In many countries, spironolactone is marketed only 
as tablets. This is an ongoing problem for some groups 
of the population such as children, patients who cannot 
swallow solid dosage forms, patients who must receive 
medications via nasogastric or gastronomy tubes, and 
patients who require nonstandard doses that are more 
easily and accurately measured using a liquid formula-
tion (10). 
From birth to adulthood, a series of anatomical, physi-
ological, and biochemical modifications are produced 
that affect the absorption, distribution, metabolism, and 
excretion of drugs and their mechanisms of action, as well 
as enzyme synthesis and the production and distribution 
of receptors (11, 12). Thus, drug prescribing must be based 
on knowledge of pharmacokinetic and pharmacodynamic 
characteristics (13).
Studies of novel dosage forms, such as mini-tablets, 
that are more appropriate for children (14) are now being 
carried out. However, orally administered liquids are still 
considered one of the standard forms for this population. 
Extemporaneous oral liquid medicines are easily prepared 
and allow dosage flexibility (1, 15). A single liquid pediatric 
preparation may be used for infants and children of all ages, 
with the dose of the drug varied by the volume adminis-
tered (16). It is common practice for liquid dosage forms to 
be prepared from a commercially available oral solid dos-
age by simply crushing tablets or opening a capsule (10). 
However, the use of an active pharmaceutical ingredient 
(API) obtained by modifying a commercially available tablet 
or capsule could have clinical and legal implications (17).*Corresponding author.
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Therefore, due to the lack of products tailored to the 
needs of this population, especially newborns, pharma-
ceutical compounds (solutions or suspensions) need to be 
prepared as an alternative to marketed tablets. However, 
there is limited information on the suitability and stability 
of liquid preparations (18). The variability in the design of 
such preparations, sometimes with unknown low stabil-
ity, leads to the possibility of medication errors in the 
handling of the dosages. Furthermore, dosage or stability 
control is not carried out in pharmacies or hospitals, as 
the indicators are determined by methods such as high 
performance liquid chromatography (HPLC) that require 
considerable effort (19). 
Over the last 30 years, many extemporaneously pre-
pared spironolactone-containing oral liquid formula-
tions have been reported in the literature (1, 20–26), and 
data on their physical and chemical stability have been 
gathered. However, some of them were prepared us-
ing crushed tablets; others contain alcohol, which is not 
desirable for children, to improve stability or drug solubil-
ity. Due to genetic polymorphism, metabolism of alco-
hol could differ among races. As these preparations are 
addressed to a pediatric population, it is desirable to avoid 
the presence of alcohol in these formulations. Other stud-
ies were carried out at a different temperature. Therefore, 
the purpose of the present study was to investigate four 
alcohol-free suspensions of spironolactone (pure powder) 
that are suitable for a pediatric population and compare 
their physical and chemical stability at three different tem-
peratures, to ensure the quality and the right preparation 
and storage of these preparations. Additionally, to assess 
the influence of the excipients on the release of the active 
substance, the dissolution profile of each suspension was 
analyzed and compared with that of the marketed tablets. 
A microbiological study of the best formulation was also 
carried out.
MATERIAL AND METHODS 
Materials
Spironolactone, simple syrup, glycerin, carboxymeth-
ylcellulose, Excipient Acofar for Syrup (sucrose, water, 
sorbitol, glycerin, flavoring, citric acid, methylparaben, 
potassium sorbate, sodium phosphate, and coloring), and 
Excipient Acofar for Suspensions (water, sodium carboxy-
methylcellulose, cellulose gum, citric acid, calcium sulfate, 
sodium phosphate, methylparaben, carrageenan, xanthan 
gum, potassium sorbate, sucrose, sorbitan triestearate, 
PEG-40 stearate, dimethicone, and silica) were purchased 
from Acofarma, S.A. (Barcelona, Spain). The tablets con-
taining 25 mg of spironolactone (commercially available 
in Spain) that were used for the dissolution test were 
purchased from a community pharmacy. Methanol was 
purchased from Panreac (Barcelona, Spain), and double-
distilled water was used after filtration in a Milli-Q Gradi-
ent A10 system apparatus (Millipore Ibérica S.A.U., Madrid, 
Spain). All chemicals were of analytical grade.
Preparation of Spironolactone Suspensions
The composition of the four suspensions of spironolac-
tone is shown in Table 1. 
To make Suspension I (SpI), simple syrup was placed in 
a glass container and spironolactone was added to the 
simple syrup under mechanical stirring (UltraTurrax, Ika, 
Germany) until a homogeneous suspension was achieved. 
To prepare Suspension II (SpII), spironolactone was mixed 
with glycerin until a homogeneous white paste was formed. 
Then, simple syrup was added slowly under stirring. To pre-
pare Suspension III (SpIII), spironolactone was mixed with 
glycerin until a homogeneous white paste was formed. 
Then, 20 g of a carboxymethylcellulose gel prepared the 
day before at a concentration of 1% was added. Once 
everything was well mixed, simple syrup was added slowly 
under magnetic stirring. For the preparation of Suspension 
IV (SpIV), spironolactone was mixed with glycerin until a 
homogeneous white paste was formed. Then, Excipient 
Acofar for Suspension was added under stirring, and finally 
the mixture was brought to volume with Excipient Acofar 
for Syrups. As a control, the same amounts of each formula-
tion (SpI, SpII, SpIII, and SpIV) without spironolactone (blank 
samples) were prepared similarly. All the formulations, with 
and without spironolactone, were stored under the same 
conditions for further analysis.
Stability Test and Suspension Characterization
After the preparation, aliquots of 10 mL of the suspen-
sions were stored in amber glass vials at three tempera-
tures (4, 25, and 40 °C) for 2 months. Measures were 
performed at selected times at 0, 7, 15, 30, and 60 days. 
Table 1. Spironolactone Suspension Composition 
Component SpI SpII SpIII SpIV
Spironolactone (mg) 500 500 500 500
Glycerin (% m/v) - 10 10 5
Carboximetylcelulose (% m/v) - - 0.2 -
Symple syrup (mL) q.s. 100 q.s. 100 q.s. 100 -
Excipient Acofar for Suspensions (mL) - - - 50
Excipient Acofar for Syrups (mL) - - - q.s. 100
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Analyses involved the physical and chemical testing of 
quantifiable parameters that could possibly change dur-
ing storage, such as appearance, rheological behavior, 
particle size, optical stability by multiple light scattering, 
pH, and active substance quantity. Microbiological stabil-
ity was also assessed. 
Preparations were considered stable if the physical 
characteristics did not change and the drug concentration 
remained greater than 90% of the original concentration (1).
Physical Stability
Appearance
The samples stored at each temperature were visually 
examined to assess parameters such as odor, color, and 
tendency to precipitate or float. 
Rheological Behavior
The rheological behavior of the formulations was as-
sessed at 25 °C using a rotational HAAKE Rheostress 1 
rheometer (Thermo Fisher Scientific, Karlsruhe, Germany) 
equipped with a parallel plate geometry setup, with a 
fixed lower plate and an upper plate (Haake PP60 Ti, 6 cm 
diameter). Different gaps between plates were tested, 
and a separation of 0.5 mm was selected. Viscosity curves 
and flow curves (n = 3) were recorded for 3 min during 
the ramp-up period from 0 to 100 s-1, 1 min at 100 s-1 (the 
constant shear rate period), and 3 min during the ramp-
down period from 100 to 0 s-1. The viscosity values at 100 
s-1 were determined at t0 and t = 60 days for the samples 
stored at 4, 25, and 40 °C. 
Data from the flow curve (when it showed that the fluid 
was non-Newtonian) were fitted to various mathematical 
models: Ostwald–de Waele, Carreau–Yasuda, Cross, and 
Herschel–Bulkley. 
Ostwald–de Waele
Carreau–Yasuda 
Cross
Herschel–Bulkley 
where τ is the shear stress, γ is the shear rate (1/s), τ0 is 
the yield shear stress (Pa), γ0 is the zero shear rate (1/s), η 
is the infinite shear rate viscosity, η0 is the zero shear rate 
viscosity (Pa∙s), k is the consistency coefficient(s), and n is 
a dimensionless rate constant. The fluid is Newtonian if 
n = 1, pseudoplastic if 0 < n < 1, and dilatant if n > 1.
Particle Size
The particle size distribution (PSD) of the spironolactone 
suspensions was carried out by laser diffraction (LD, 2000E 
Mastersizer, Malvern, UK). The average particle size distri-
bution was measured from six replicates of each sample. 
Suspensions were diluted with purified water. Data were 
evaluated using the volume distribution method, and 
characterization parameters were D10, D50, and D90 (i.e., 
D90 of 1 µm means that 90% of volume of particles have 
a diameter of 1 µm or less). To evaluate the changes in the 
PSD of the suspensions, samples stored at room tempera-
ture (25 °C) were measured at days 0 and 60.
Prediction of Long-Term Physical Stability of the Suspensions 
Technology based on the analysis of multiple light 
scattering was used to predict the long-term physi-
cal stability of suspensions. Turbiscan Lab (Formulac-
tion Co., L’Union, France) is an optical instrument that 
characterizes concentrated emulsions and dispersions. 
The analyzed suspension is placed on a cylindrical glass 
measuring cell. The light source is pulsed near infrared 
(λ = 880 nm). Two synchronous optical sensors receive 
light transmitted through the sample (0° from the 
incident radiation, transmission [T] sensor) and light 
backscattered by the sample (135° from the incident 
radiation, backscattering [BS] detector). The principle of 
this measurement is based on variation in the particle 
volume fraction (migration) or mean size (coalescence), 
which results in variations in the BS and T signals (27–29). 
Therefore, this technique was used to detect changes 
in the location of particles in the suspensions. Measure-
ments were performed at 25 °C.
Chemical Stability
pH Measurements
The pH values (n = 3) were measured by immersing 
the probe directly into the sample using a digital pH/mV 
meter (Micro-pH 200, Crison Instruments S.A., Barcelona, 
Spain). The pH was measured at three temperatures at 
selected times (0, 7, 15, 30, and 60 days). A significant 
variance in pH over an adequate value per formula could 
indicate degradation of the pharmaceutical compounding 
or erroneous preparation. 
Suspension Uniformity and Spironolactone Stability
Homogeneity of the suspensions was examined at t = 0 
to ensure that every vial contained not less than 90% and 
no more than 110% of the theoretically calculated and 
labeled amount of spironolactone per unit volume. Six 
samples were taken from each vial, and spironolactone 
content was assayed using the high performance liquid 
chromatography (HPLC) method described below. Rela-
tive standard deviation (%RSD) was used to assess the 
homogeneity of the suspensions. 
To evaluate the stability of spironolactone in the sus-
pensions stored at the three temperatures, an analysis 
(n = 6) was carried out during the storage period (at 0, 7, 
15, 30, and 60 days) using the HPLC quantification tech-
nique described below. Preparations were considered 
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stable if the active substance was within ±10% of the 
original amount.
To carry out the analysis, 250 µL of suspension equiva-
lent to 1.25 mg of spironolactone was diluted with 100 
mL of methanol/water (30:70) in an amber glass flask to 
obtain a final spironolactone concentration of 12.5 µg/mL. 
The solution was sonicated for 1 min in an ultrasonic bath 
(P-selecta 514, Vidrafoc, Barcelona, Spain) and then spot-
ted and analyzed for spironolactone content.
Apparatus and Conditions
The HPLC system consisted of a Waters 717 Plus au-
tosampler (Waters, Milford, MA, USA) equipped with an 
Atlantis dC18 column (4.6 × 150 mm, 5-µm) and a UV–vis 
detector (Waters, Milford, MA, USA) set at 242 nm. The 
mobile phase was methanol/water (37:63) delivered at a 
flow rate of 0.8 mL/min. It was filtered through a 0.45-µm 
membrane and degassed by sonication prior to use. The 
injection volume was 50 µL.
To assess the presence of canrenone, the main deg-
radation product of spironolactone (30), a preliminary 
comparative study at 242 and 280 nm was carried out on 
a sample stored at 70 °C for 15 days under the conditions 
mentioned above.
Analytical Validation Calibration Standards
Calibration curves containing six standards from 25 
to 0.78 µg/mL (25, 12.5, 6.25, 3.13, 1.56, and 0.78 µg/mL) 
were prepared by making dilutions with appropriate vol-
umes of methanol/water (30:70).
The methodology was validated according to Interna-
tional Conference on Harmonization guidelines Q2 (R1) 
(31, 32) and included an evaluation of the following char-
acteristics: linearity, sensitivity, precision, accuracy, and 
limits of detection and quantification.
Calibration curves were validated interday (n = 6). A 
linear regression analysis was performed. Furthermore, 
linearity was determined by a one-way analysis of vari-
ance (ANOVA) test of response factors (ratio of peak areas 
versus nominal concentrations of each standard), and 
differences were considered statistically significant when 
p < 0.05.
The selectivity of the assays was checked by individual 
analysis of blank samples stored at the corresponding 
temperatures.
The determination of the limits of detection (LOD) and 
quantification (LOQ) was based on the standard deviation 
of the response (SD) and the slope of the calibration curve 
(S) according to the following equations: 
LOD = 3.3 (SD/S)    and    LOQ = 10 (SD/S)
Accuracy was evaluated by means of the relative error (%), 
and intermediate precision was expressed as the relative 
standard deviation (RSD) of replicates in percentage. The 
maximum acceptable levels were 10% in both cases.
Dissolution Test (In Vitro Drug Release Studies)
The test was performed according to USP <711> (33) 
using a paddle apparatus (Apparatus 2) SR8 PLUS (Han-
son Research, Canada) at 37 °C and 75 rpm. Tablets or 
the suspensions (equivalent to 25 mg of spironolactone) 
were held in different vessels (1000 mL). The suspension 
sample (5 mL) was taken using a syringe and quantita-
tively transferred to the vessel at the top of the dissolu-
tion medium. To calculate the exact weight of suspension 
added to the vessel, the syringe was weighed at three 
stages: empty, filled with the suspension, and after the 
sample was expelled into the dissolution vessel. Aliquots 
were removed from the vessel and replaced with fresh 
dissolution medium (0.1 N HCl containing 0.1% sodium 
lauryl sulfate) at predetermined time intervals. For rapidly 
dissolving products including suspensions, useful infor-
mation may be obtained from earlier points (33), thus 
aliquots were removed at 2, 5, 8, 12, 15, 20, 25, 30, 40, 50, 
and 60 min for the tablets and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11, 12, 13, 14, 15, and 60 min for the suspensions. Spirono-
lactone content was analyzed by spectrofluorometry at 
242 nm using an Amersham Biosciences Ultrospec 1100 
Pro UV–vis spectrophotometer (Amersham Biosciences, 
Piscataway, NJ, USA) at room temperature.
The method for quantifying spironolactone was also 
validated following the procedure described above. In this 
case, the solvent for the preparation of standard solutions 
was the dissolution medium.
Three kinetic models (a one-phase exponential asso-
ciation, a two-phase association model, and Boltzmann 
sigmoid) were used to fit the experimental data from the 
drug release experiment: 
One-phase 
exponential 
association
Two-phase 
association 
model
Boltzmann 
sigmoid
A nonlinear regression was performed using Prism 
software, V. 3.00 (GraphPad Software Inc., San Diego, CA, 
USA). In addition, Akaike’s information criterion (AIC) was 
determined for each model, as it is an indicator of model 
suitability for a given data set (34). The smaller the value of 
AIC, the better the model fits the data.
In addition, some non-model parameters such as dis-
solution efficiency (DE) and mean dissolution time (MDT) 
were calculated from the in vitro release data. These 
parameters are very useful for comparing profiles types, 
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as an evaluation of the dissolution characteristics of the 
formulations is not conditioned by the goodness of the 
fit to a theoretical model of our data (35). The DE(%) was 
calculated by means of the following equation:
where the numerator represents the area under the dis-
solution curve up to a certain time t, and the denominator 
is the rectangular area between the total amount of drug 
released and the last experimental time point t. For the 
area under the dissolution curve (AUC) calculation, a con-
tinuous plot of the evolution of released quantities across 
the whole of the experimental time was calculated. After-
wards, respective AUC values were calculated by means of 
a trapezoidal rule for the whole time values interval. 
MDT is defined as the mean residence time of a drug in 
the formulation. It is a useful parameter for characterizing 
drug release rate from a dosage form. It was calculated 
using the equation:
where i is the sample number, n is the number of dissolu-
tion sample times, –ti is the time at the midpoint between 
ti and ti−1 calculated with the expression (ti + ti−1)/2, ΔMi is 
the increase in the amount of drug released at each time 
interval, and M∞ is the asymptote of the dissolved amount 
of drug.
Microbiological Stability
A microbiological test of the suspension that had the 
best characteristics was performed according to the Euro-
pean Pharmacopoeia monograph, Microbiological exami-
nation of non-sterile products (30). The microbial count is 
the average number of colony forming units (cfu) found in 
agar. Oral solutions meet microbial requirements if the to-
tal aerobic microbial count is below 102 cfu/mL, the total 
combined yeast/mold count is below 101 cfu/mL, and the 
absence of Escherichia coli is confirmed.
Statistical Analysis
Data were statistically analyzed by the Student’s t-test 
or one-way ANOVA for comparisons of three or more 
groups of data. The level of significance was set at p < 0.05 
using Prism V.3 software (GraphPad Software, Inc., San 
Diego, CA).
RESULTS AND DISCUSSION
The preparation of extemporaneous formulations often 
involves the use of commercial dosage forms and their 
conversion into something patients can easily swallow 
(36). However, the use of an API from the modification 
of a commercially available tablet or capsule could have 
legal and clinical implications (17). Therefore, pure powder 
was used to prepare the solutions. Glycerin was used 
to decrease the interfacial tension between the drug 
as a solid and the rest of the liquid, as spironolactone is 
practically insoluble in water. In SpIII, a suspending agent 
(carboxymethylcelullose) was chosen to increase viscosity 
and keep the suspended solid homogeneously distributed 
inside the formulation for longer. A concentration of 0.2% 
(w/v) was enough for this purpose. Excipient Acofar for 
Syrups and Excipient Acofar for Suspensions, used in SpIV, 
are commercially available in some European countries 
and are useful to pharmacists in the preparation of formu-
lations.
Physical Stability
All the formulations were redispersible suspensions. 
SpI, SpII, and SpIII were white, whereas SpIV was slightly 
pink with a characteristic fruity odor at t0. There were 
no detectable changes in color and odor in any sample 
during the two months of storage at the three controlled 
temperatures.
Oral viscosity plays an important role in the perception 
of the texture of liquid or fluid pharmaceuticals. Several 
instrumental measurements have been described to 
correlate closely with perceived viscosity and therefore 
describe the thickness signal interpreted by the brain. 
For example, oral shear stress is calculated from the as-
sumption that the mouth is comparable to parallel plate 
geometry on a rheometer (37). Viscosity measurements 
were made with an imposed shear rate (γ), and the result-
ing shear stress (τ) was measured. This type of test can be 
used to determine if the material is characterized by lin-
ear–viscous (Newtonian) behavior (shear-stress exponent 
n = 1) in the investigated shear rate range or if it shows 
power-law behavior (n ≠ 1). The potential dependence of 
the viscosity of the solutions on the shear rate is shown in 
Figure 1.
The curves for SpI and SpII show constant viscosity 
values with an increasing shear rate from 0 to 100 s-1, and 
thus the behavior was Newtonian. In both cases, the slope 
of the flow curve is constant, and the graph of viscosity 
is a line (38, 39). The curves for SpIII and SpIV are slightly 
dependent on shear rate, showing a consistent, although 
relatively small, decrease in viscosity with increasing 
shear rate from 0 to 100 s-1. This is the typical behavior 
of pseudoplastic fluids. In all cases, the hysteresis loop is 
inappreciable, which indicates that SpIII and SpIV did not 
show thixotropy.
Viscosity values at 100 s-1 were 0.110, 0.130, 0.450, and 
0.030 Pa∙s for SpI, SpII, SpIII and SpIV, respectively, at t0. As 
shown in Table 2, no statistically significant differences 
were observed at t60 for the samples of all the suspensions 
stored at 4 and 25 °C. A small decrease in the viscosity of 
SpIII and SpIV was observed (p < 0.05) at t60 in the samples 
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stored at 40 °C. This is the normal behavior of CMC solu-
tions (40). Rheological stability is an important require-
ment, because the dosage process should ensure uniform 
distribution of the active substance within the suspension, 
especially among pediatric patients. 
The suspensions that contained simple syrup had 
higher viscosity values than SpIV due to the higher con-
centration of sucrose. SpIII had the highest viscosity value, 
probably due to the mixture of carboxymethylcelulose 
and simple syrup (40). Glycerin did not influence viscosity, 
as SpI and SpII had similar viscosity values. 
For SpIII and SpIV (pseudoplastic), Ostwald–de Waele, 
Carreau–Yasuda, Cross, and Herschel–Bulkley mathemati-
cal models were fitted to the data of the flow curve to 
identify the model that provided the best overall match 
of the experimentally observed rheological data. The 
criterion for selecting the most appropriate model was 
based on finding the best fit, with the highest correlation 
coefficient of the linear regressions (r) and the lowest chi 
square value. Such a model provided the best statistical 
description of the rheological behavior. The model that 
best fit the experimental data in all cases was Cross, prob-
ably due to the presence of CMC (41). The accompanying 
results of the Cross model constants are listed in Table 3. 
In both cases, the rate index n remains constant at the end 
of the study regardless of the temperature. 
Physical characteristics, particularly the particle size of 
the drug substance, are very important for suspensions 
(42). The PSD in the finished drug product dosage form is 
a critical parameter that significantly affects the bioavail-
ability and pharmacokinetics of the product (43). Particle 
size was determined by LD at day 0 (just after the prepara-
tion of the suspensions) and at the end of the study (t60).
All of the suspensions were coarse dispersions (as clas-
sified by Ostwald), since the particle size was greater than 
1 µm. Particles in suspension have a surface free energy 
that makes the system unstable. The free energy of the 
system depends on the total surface area and the inter-
facial tension between the liquid medium and the solid 
particles. Thus, to minimize the free energy, the system 
tends to decrease the surface area, which is achieved by 
the formation of agglomerates (43). This was the case for 
SpI, which was the suspension with the largest particle 
size. SpII, SpIII, and SpIV had smaller particle sizes, as the 
presence of a wetting agent helps to lower the liquid–air 
interfacial tension. This enables the solvent to penetrate 
into the loose agglomerates of powder and thus displace 
the air from the pores of the individual particles (43). The 
results (Table 4) show that the distribution was consistent 
for SpI over the 60-day period, as both D10% and D90% 
were stable after 60 days. A very slight increase in PSD by 
day 60 in comparison with the values obtained at t0 was 
observed for SpII, SpIII, and SpIV.
Turbiscan Lab, an optical analyzer, was also used to 
detect destabilization phenomena. In comparison with 
classical stability measurements, this technique assesses 
physical stability without diluting or modifying the 
formulation (29). To assess the optical stability, Turbiscan 
Lab scans at various preprogrammed times and overlays 
the profiles on one graph to show the destabilization. 
Migration phenomena are displayed by local variations of 
backscattering (Figure 2). Backscattering fluxes are shown 
on the ordinate, and the height of the cell on the abscissa. 
The first profile is displayed in pink, and the last one in 
red. As expected, all of the suspensions were unstable 
systems. In SpIV, the backscattering level dropped at the 
top (right side of the spectrum) due to a decrease in the 
concentration of particles. Hence, the suspension clarified 
in this area. At the bottom of the suspension, there was 
an increase in particle concentration because of sediment 
Table 2. Suspension Viscosity (Pa∙s) at t60 at 4, 25, and 40 °C
Suspension Temperature
4 °C 25 °C 40 °C
SpI 0.108 ± 3.4x10-3 0.107 ± 3.1 x10-3 0.106 ± 4.3 x10-3
SpII 0.123 ± 2.9 x10-3 0.120 ± 4.7 x10-3 0.106 ± 4.3 x10-3
SpIII 0.453 ± 3.0 x10-3 0.445 ± 3.6 x10-3 0.408 ± 1.1 x10-3 (*)
SpIV 0.453 ± 3.0 x10-3 0.031 ± 9.4x10-4 0.022 ± 7.9 x10-4 (*)
* Statistical significant differences (p < 0.05) regarding t = 0.
Figure 1. Rheograms of Suspensions (a) I, (b) II, (c) III, and (d) IV. The red line 
is shear stress (Pa), and the blue line is viscosity (Pa∙s). 
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formation. The presence of solvents and cosolvents (sor-
bitol, glycerin, PEG-40) in SpIV, together with suspending 
agents like carrageenan, which is a hydrophilic colloid that 
coats hydrophobic particles, and flocculating agents (cal-
cium sulfate, sodium phosphate), helped the sedimenta-
tion of spironolactone, as shown in Figure 2. The presence 
of these ingredients in SpIV could also explain the second 
PSD obtained at day 60. Something different occurred for 
SpI, SpII, and SpIII, in which the backscattering level de-
creased at the bottom (clarification) and increased at the 
top. This behavior could indicate that the chosen wetting 
agent, glycerin, was not enough to wet the particles of spi-
ronolactone, and thus flotation was observed. Destabiliza-
tion was slower for SpIV than for the other suspensions. 
This characteristic is desirable, as it allows the formulation 
to remain homogenous longer. All the formulations were 
resuspendable, despite the occurrence of flotation or sedi-
mentation. However, to achieve good redispersion of the 
particles and thus a homogeneous and correct dosage, 
sedimentation is more desirable than flotation.
Chemical Stability
The pH of SpIV was around 4.5, which is the optimum 
pH of spironolactone as reported in the literature (44). 
SpI, SpII, and SpIII had pH values of around 6.5, prob-
ably due to the presence of potassium sorbate from the 
simple syrup (1), which does not contain any other acidic 
substances. In all cases, the measured pH remained fairly 
constant after two months of study (Table 5). As reported 
by other authors (1), the pH was not affected by tempera-
ture in any of the formulations. The above-optimum pH 
for spironolactone that was observed in SpI, SpII, and SpIII 
did not affect the amount of active ingredient present in 
the different formulations.
No peaks attributable to canrenone were detected 
after a preliminary comparative study carried out at 242 
Table 3. Fitted Parameters for Effect of Temperature and Time on Flow Behavior of SpIII and SpIV
Parameter
Time/Temperature Formulation 0 ∞ 0 n Chi2 r
t0 (25 °C) Suspension III 1.706 0.226 12.090 0.625 0.442 1
Suspension IV 0.186 0.014 1.217 0.516 0.003 1
t60 (4 °C) Suspension III 1.268 0.202 14.570 0.645 0.686 1
Suspension IV 0.249 0.015 0.513 0.539 0.001 1
t60 (25 °C) Suspension III 0.752 0.103 96.66 0.565 0.079 1
Suspension IV 0.181 0.015 0.777 0.538 0.005 1
t60 (40 °C) Suspension III 0.727 0.180 51.340 0.703 0.034 1
Suspension IV 0.106 0.014 2.717 0.691 0.002 1
Table 4. Particle Size Distribution of the Suspensions at t0 and t60
Particle size (μm)
t0 t60
d10% d50% d90% d10% d50% d90%
SpI 16.2 ± 0.2 35.4 ± 0.8 73.7 ± 0.5 15.4 ± 0.5 28.4 ± 0.7 73.1 ± 0.9
SpII 6.6 ± 0.5 14.1 ± 0.8 27.9 ± 0.9 8.2 ± 0.8 16.3 ± 0.9 30.4 ± 0.8
SpIII 5.5 ± 0.2 12.7 ± 0.2 26.9 ± 0.6 9.1 ± 0.6 17.8 ± 0.9 33.1 ± 0.4
SpIV 8.8 ± 0.8 18.2 ± 0.9 33.3 ± 0.7 10.7 ± 0.4 21.3 ± 0.7 41.9 ± 0.9
Figure 2. Backscattering profiles for suspensions (a) SpI, (b) SpII, (c) SpIII, 
and (d) SpIV.
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and 280 nm. Thus, spironolactone was assayed during 
the stability study under the specified conditions at 242 
nm (the maximum wavelength of absorbance for spi-
ronolactone). The HPLC method for the quantification 
of spironolactone in the suspensions was linear, precise, 
and accurate in the concentration range of 25–0.78 µg/
mL. LOD and LOQ are 0.22 ± 0.26 µg/mL and 0.68 ± 0.79 
µg/mL, respectively, which confirm the sensitivity of the 
method. The accuracy values reported in Table 6 are 
within acceptable limits (<10%). The small percentage 
differences between the nominal and found concentra-
tions of the standards show that the assay is accurate 
enough for its application. The between-day precision 
results are also depicted in Table 6, and the RSD val-
ues are less than 10% at all concentrations. These data 
clearly indicate that the assay method is reproducible 
between days.
The method was selective under the aforementioned 
chromatographic conditions, as the excipient peaks did 
not interfere with the spironolactone peak, which did not 
change and remained at the same retention time (about 
12.0 min) throughout the study (Figure 3). 
Regarding the uniformity of the suspensions, the mean 
recovery (%) for all of them was within the acceptable 
interval ±10% of the labeled amount, as shown in Table 7. 
SpIII showed the lowest percent recovery and the highest 
RSD (%), probably due to its higher viscosity that allows 
the particles to remain in suspension longer, but also 
makes redispersion more difficult.
The analytical results show that the spironolactone 
content of all suspensions remained above 90% (w/v) of 
the original amount throughout the 60-day study, regard-
less of temperature. There were no statistically significant 
differences in the content of spironolactone for SpI, SpII, 
and SpIV between t0 and t60. However, as shown in Figure 
4 and in line with the mean recovery (%) results, SpIII 
registered statistically significant variability (p < 0.05) in 
spironolactone content at 4 and 25 °C. This variability was 
probably due to the higher viscosity at these tempera-
tures, which could hinder sampling and the homoge-
neous distribution of spironolactone in the suspension. 
Higher temperatures decreased the viscosity of the for-
mula, which facilitated sampling and homogeneity, and 
thus at 40 °C the results were more constant. Therefore, 
Table 5. Suspension pH Values (Median) at Different Times and Temperatures
Formulation Temperature (°C)
Time (Days)
0 7 15 30 60
Suspension I 4 - 6.9 ± 0.03 6.6 ± 0.03 6.5 ± 0.70 6.3 ± 0.20
25 6.5 ± 0.03 7.0 ± 0.04 6.6 ± 0.02 6.2 ± 0.30 6.0 ± 0.30
40 - 6.7 ± 0.02 6.5 ± 0.01 6.1 ± 0.40 6.0 ± 0.30
Suspension II 4 6.9 ± 0.02 6.9 ± 0.03 6.7 ± 0.20 6.1 ± 0.10
25 6.6 ± 0.1 6.9 ± 0.02 6.8 ± 0.02 6.8 ± 0.20 6.2 ± 0.20
40 6.7 ± 0.03 6.7 ± 0.01 6.5 ± 0.10 6.4 ± 0.20
Suspension III 4 6.5 ± 0.02 6.5 ± 0.03 6.5 ± 0.03 6.0 ± 0.10
25 6.4 ± 0.30 6.6 ± 0.06 6.5 ± 0.03 6.5 ± 0.01 6.0 ± 0.10
40 6.6 ± 0.03 6.4 ± 0.07 6.2 ± 0.01 6.1 ± 0.07
Suspension IV 4 - 4.3 ± 0.08 4.2 ± 0.03 4.2 ± 0.06 4.1 ± 0.01
25 4.2 ± 0.01 4.2 ± 0.01 4.1 ± 0.01 4.2 ± 0.01 4.1 ± 0.01
40 - 4.2 ± 0.02 4.2 ± 0.05 4.2 ± 0.02 4.2 ± 0.01
Table 6. Accuracy and Precision Parameters for Spironolactone Quantification
Concentration (μg/mL) Average Standard Deviation Relative Error (%) Relative Standard Deviation (%)
 50 50.01 0.104 -0.035 0.208
 25 25.00 0.223 -0.001 0.894
 12.5 12.40 0.385 0.777 3.101
 6.25 6.28 0.098 -0.490 1.429
 3.125 3.16 0.077 -1.083 2.193
 1.56 1.57 0.045 -0.947 2.882
 0.78 0.79 0.074 -0.824 9.454
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based on the results, spironolactone was stable in all the 
studied formulations for 60 days at 4, 25, and 40 °C.
Dissolution Test
Dissolution studies have great significance because, in 
most cases, drug dissolution is the rate-limiting step in 
the absorption process. As occurs with solid oral dosage 
forms, heterogeneous disperse systems (suspensions) 
could also have some problems with in vitro dissolution 
(45).
The dissolution test of the suspensions was performed 
and the results were compared with the dissolution 
profiles of the commercially available tablets (25 mg of 
spironolactone).
In vitro dissolution has been recognized as an important 
element in drug development, and under certain condi-
tions, it can be used as a potential surrogate marker of 
bioequivalence (46, 47).
This comparative study has not yet been reported in 
the literature, but it is very important, as the composi-
tion of the suspensions could modify the dissolution 
time and affect the velocity of absorption of the active 
substance. The UV spectrophotometric method used to 
quantify spironolactone in the dissolution test was linear, 
accurate, and precise over a range of concentrations from 
1.56 to 25 µg/mL. The LOD and LOQ were 0.19 ± 0.16 µg/
mL and 0.60 ± 0.50 µg/mL, respectively. Accuracy values 
(%RE) were less than 6.06% and thus within acceptable 
limits (<10%). The small percentage difference between 
the nominal and found concentration of the standards 
show that the assay is accurate enough for its application. 
Results for between-day precision (%RSD), ranging from 
0.30 to 6.30%, clearly indicate that the assay method was 
reproducible between days.
The in vitro drug release test revealed that SpI, SpII, and 
SpIV dissolved almost immediately. However, this was not 
the case for SpIII, which took around 10 min to achieve the 
maximum concentration of active substance. The delay in 
the release of spironolactone in SpIII could be due to the 
presence of CMC together with simple syrup. Thus, the 
presence of these excipients could lead in variations in the 
velocity of spironolactone absorption. 
The dissolution profiles of SpIII and the marketed tablets 
were compared. Parameters that were independent of the 
release model, such as DE and MDT, were calculated with 
the experimental values (n = 6) for both formulations. The 
results are shown in Table 8. As expected, MDT was higher 
and DE was lower for the tablets than for the suspension. 
A criterion for selecting the most appropriate drug 
release model was based on the best fitting model, which 
had the lowest value of AIC and the highest correlation 
Table 7. Recovery (%) of the Suspensions
Formulation Drug content (mg) Found (mg) % Mean Recovery (n = 6) Relative Standard Deviation (%)
Suspension I 500 499.36 99.87 3.06
Suspension II 500 502.27 100.45 4.73
Suspension III 500 485.58 97.11 9.28
Suspension IV 500 496.92 99.38 1.34
Figure 3. Chromatographic profiles of the  (a) spironolactone standard; 
superposed chromatograms of blank (blue line) and sample (black line) for 
suspensions (b) SpI, (c) SpII, (d) SpIII, and (e) SpIV.
Figure 4. Stability of spironolactone in the suspensions over 60 days for sus-
pensions (a) SpI, (b) SpII, (c) SpIII, and (d) SpIV.
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coefficient of the linear regression (r2) and thus statistically 
described the best drug release mechanism. For SpIII, the 
model that best fit the data was the Boltzmann sigmoid. 
In general, the Boltzmann model is used to simulate the 
transport and reaction of fluids in porous media (48). In 
this case, the polymer (CMC) probably performs a function 
similar to porous matrices and, therefore, presents the 
same model. Other authors (49) used a coupled multi-
phase lattice Boltzmann model to simulate the dissolu-
tion of immiscible liquid droplets in another liquid during 
the rising process resulting from buoyancy. However, for 
the tablets, a two-phase exponential association model 
fit the data best. This model is used when the measured 
outcome is the result of the sum of a fast and slow expo-
nential decay. In our case, this could be due to the quick 
dissolution of the film coat of the tablets at the beginning 
and a subsequent slow disintegration due to the excipi-
ents (calcium sulfate or cornstarch) that limits the dissolu-
tion process.
Best-fit and goodness-of-fit values for both models are 
reported in Table 9. The mean dissolution profiles (n = 6) 
for SpIII and for the tablet are shown in Figure 5. 
Microbiological Stability
Microbial contamination in nonsterile liquid formula-
tions may cause a foul odor, turbidity, and adversely affect 
palatability and appearance. Otherwise, a high level of 
microorganisms may be hazardous to health, especially in 
immunocompromised patients.
Taking into account all the studied parameters, the 
microbiological test of SpIV was performed. No E. Coli 
contamination was observed, the total bacteria count was 
below 102 cfu/g, and the fungal contamination was below 
101 cfu/g at day 60 of the study. These results indicate 
that SpIV complied with the European Pharmacopoeia 
specifications on the microbial examination of non-sterile 
product at 60 days.
CONCLUSIONS
Four alcohol-free extemporaneous suspensions contain-
ing 5 mg/mL of spironolactone were prepared from drug 
powder. In general, the spironolactone extemporaneous 
formulation was kept as simple as possible, using simple 
syrup as the only selected vehicle. However, this suspen-
sion had the largest particle size, and flotation occurred. 
Glycerin, used as a wetting agent, was not enough to wet 
the particles in SpII and SpIII. The results suggest that 
SpIII was the least suitable due to its high viscosity, which 
made it difficult to achieve homogeneous redispersion. An 
accurate dosage is always very important, especially in the 
pediatric population. Furthermore, drug release in SpIII 
was slower than in the other formulations, which indicates 
that the presence of some excipients could have an influ-
ence on the dissolution profile of the suspensions. Only 
Table 9. Best-Fit Values and Goodness of Fit for Boltzman Sigmoid (Suspension) and Two-Phase Exponential Association (Tablets)
Best-Fit Values for Suspension III Goodness of Fit (Boltzman sigmoid)
Bottom 2.33 mg Degrees of Freedom 10
Top 25.61 mg R2 0.9967
V50 5.16 min Absolute sum of squares 2.481
Slope 1.61 min Sy.x 0.4981
Best-Fit Values for Tablets Goodness of Fit (Two-phase exponential)
YMAX1 -5.20 mg Degrees of Freedom 7
K1 0.62 min-1 R2 0.9999
YMAX2 31.18 mg Absolute sum of squares 0.08646
K2 0.12 min-1 Sy.x 0.1111
Halflife_1 1.10 min
Halflife_2 5.76 min
Table 8. Dissolution Parameters Independent of the Model
Formulation MDT (min) AUC (mg min) DE (%)
Tablet 10.2 1317.8 82.9
Suspension III 4.8 1403.0 91.8
AUC: area under the curve; MDT: mean dissolution profile; DE: Dissolution 
Efficiency. 
Figure 5. Dissolution profiles of SpIII and the marketed tablets.
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SpIV had an optimum pH and the best physical stability. 
SpIV was also microbiologically stable for at least 60 days.
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